Teva Pharmaceutical Industries Limited (LON:0LER)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 33.92B +177.8% |
| Revenue (ttm) | 13.05B +4.1% |
| Net Income | 532.11M |
| EPS | 0.45 |
| Shares Out | n/a |
| PE Ratio | 63.74 |
| Forward PE | 13.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 91 |
| Open | 38.65 |
| Previous Close | 37.10 |
| Day's Range | 38.51 - 39.40 |
| 52-Week Range | 18.21 - 39.40 |
| Beta | 0.87 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About LON:0LER
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com...
News
Teva presents new new real-world data on uzedy at Psych Congress
Teva (TEVA) Pharmaceuticals announced new real-world data evaluating treatment continuity, healthcare resource utilization and clinical outcomes among adults with schizophrenia and bipolar I disorder ...
Teva announces new olanzapine post-hoc data
Teva (TEVA) Pharmaceuticals “announced the presentation of new olanzapine LAI post hoc data from the pivotal SOLARIS Phase 3 trial as well as analyses supporting treatment switch strategies. The SOLAR...
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from a discrete choic...
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new real-world data evaluating...
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new olanza...
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
PARSIPPANY, N.J. and TEL AVIV, Israel, Sept.
Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
TEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully priced its offering of approximately $4.9 b...
Leerink starts Teva with an Outperform with new strategy ‘clearly bearing fruit’
Leerink initiated coverage of Teva (TEVA) with an Outperform rating and $45 price target Teva’s “Pivot to Growth” strategy is “clearly bearing fruit,” evidenced by strong commercial execution and a…
Teva initiated with an Outperform at Leerink
Leerink initiated coverage of Teva (TEVA) with an Outperform rating and $45 price target
Teva Announces Launch of Offering of Senior Notes
TEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue senior notes through its special purpose ...
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
Teva price target raised to $48 from $42 at UBS
UBS analyst Ashwani Verma raised the firm’s price target on Teva (TEVA) to $48 from $42 and keeps a Buy rating on the shares. The firm views the company’s Phase…
Teva's immune disorder drug meets main goal in mid-stage trial
Israeli drugmaker Teva Pharmaceutical Industries , said on Wednesday its experimental drug helped prevent gluten-related intestinal damage in adults with celiac disease, meeting the main goal of a m...
Teva reports TEV ‘408 study met primary endpoint
Teva (TEVA) announced topline results from an ongoing Phase 2a study of TEV ‘408, an investigational anti-interleukin-15 monoclonal antibody, in adults with celiac disease. The study met its primary e...
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
Teva reports positive Phase 2a results for Teva-discovered TEV '408, showing significant prevention of gluten-induced intestinal damage in celiac disease.
Trump Administration Reaches Drug Pricing Deals With 9 Companies
The agreements provide for all state Medicaid programs to pay prices for prescription drugs that match the lowest prices paid by other developed nations, the White House said
Teva to lower cost of select medicines for American patients covered by Medicaid
Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva, announced a shared commitment with the Trump Administration to lower the cost of select medicines for American patients covered by Medicaid. When...
Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.
PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a shared c...
Teva unit bids to acquire neuroscience product from BioXcel Therapeutics
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries (TEVA) announced it has made a bid to acquire an innovative neuroscience product from BioXcel Therapeutics (BTAI...
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
BXCL501, a novel dexmedetomidine sublingual film, is under FDA review for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disor...
BioXcel Therapeutics enters asset sale agreement with Teva
BioXcel Therapeutics (BTAI) announced that it has entered into an asset sale agreement with Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries (TEVA), for substant...
Aurinia settles patent litigation with Teva
Aurinia Pharmaceuticals (AUPH) announced that it and its subsidiary, Aurinia Pharma U.S., Inc., have entered into a settlement agreement with Teva Pharmaceuticals Inc. (TEVA) to resolve patent infring...
Aurinia Settles Patent Litigation with Teva
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Settles Patent Litigation with Teva.
TEVA Stock Climbs as 50-Year-Long Tourette Syndrome Drug Breakthrough Moves Closer
Shares in Teva Pharmaceutical Industries ($TEVA) were healthier today after a potential 50-year-long breakthrough treatment for Tourette syndrome moved a step closer. Ecopipam Application Accepted The...
Teva announces FDA acceptance of ecopipam NDA
Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva, announced that the FDA accepted the new drug application, or NDA, for ecopipam, with a targeted action date late in the first…